{"id":"W2892012428","doi":"10.1200/jco.2016.34.15_suppl.3546","title":"IND.210: A randomized phase 2 trial of FOLFOX6/bevacizumab with or without reovirus (Reo) in patients (pts) with metastatic colorectal cancer (mCRC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Juravinski Cancer Centre; McGill University Health Centre; Sunnybrook Health Science Centre; Queen's University; Cancer Care Ontario; Princess Margaret Cancer Centre; BC Cancer Agency; Ottawa Hospital; University of Ottawa; University of Calgary","funders":"","keywords":"Medicine; Bevacizumab; Internal medicine; Hazard ratio; Gastroenterology; Colorectal cancer; Clinical endpoint; Progression-free survival; Randomized controlled trial; KRAS; Chemotherapy; Surgery; Oncology; Confidence interval; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001218248,0.001064329,0.001143492,0.0002418399,0.000239667,0.0005902352,0.0004398995,0.0009555572,0.008561795],"category_scores_gemma":[0.000705332,0.0004494392,0.0008789717,0.0002133075,0.0006354692,0.0003926613,0.0003080604,0.001619697,0.001179383],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004298855,"about_ca_system_score_gemma":0.0009331693,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005977884,"about_ca_topic_score_gemma":0.002157998,"domain_scores_codex":[0.9997337,0.0001386318,0.00001298172,0.00004523495,0.00001789199,0.00005152552],"domain_scores_gemma":[0.999756,0.0000596256,0.00005067221,0.0000165649,0.00001425539,0.000102831],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9590361,0.005994427,0.0009339915,0.0005045943,0.0003462674,0.00006512441,0.0000452409,0.0005404713,0.006810581,0.0002582386,0.002535712,0.02292918],"study_design_scores_gemma":[0.9400089,0.05564111,0.001203554,0.00002431849,0.0001993075,0.00005847556,0.00001069354,0.0004486984,0.0006410165,0.0001485972,0.001606771,0.000008498165],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9761489,0.002233939,0.001296112,0.001115079,0.0004931382,0.009075542,0.00367797,0.000252963,0.005706314],"genre_scores_gemma":[0.9691537,0.001479228,0.003173291,0.002373921,0.0003044708,0.01067917,0.003986227,0.00003603334,0.008813936],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008561795,"threshold_uncertainty_score":0.02864206,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.073541251622984,"score_gpt":0.4775817518546719,"score_spread":0.4040405002316879,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}